316 related articles for article (PubMed ID: 31749811)
1. Regulation of the Immune Balance During Allogeneic Hematopoietic Stem Cell Transplantation by Vitamin D.
Flamann C; Peter K; Kreutz M; Bruns H
Front Immunol; 2019; 10():2586. PubMed ID: 31749811
[TBL] [Abstract][Full Text] [Related]
2. Metabolic Targets for Improvement of Allogeneic Hematopoietic Stem Cell Transplantation and Graft-vs.-Host Disease.
Tijaro-Ovalle NM; Karantanos T; Wang HT; Boussiotis VA
Front Immunol; 2019; 10():295. PubMed ID: 30891031
[TBL] [Abstract][Full Text] [Related]
3. The Role of Co-stimulatory/Co-inhibitory Signals in Graft-vs.-Host Disease.
Kumar S; Leigh ND; Cao X
Front Immunol; 2018; 9():3003. PubMed ID: 30627129
[TBL] [Abstract][Full Text] [Related]
4. Graft Engineering and Adoptive Immunotherapy: New Approaches to Promote Immune Tolerance After Hematopoietic Stem Cell Transplantation.
Bertaina A; Roncarolo MG
Front Immunol; 2019; 10():1342. PubMed ID: 31354695
[TBL] [Abstract][Full Text] [Related]
5. Non-myeloablative hematopoietic stem cell transplantation (NST) in the treatment of human malignancies: from animal models to clinical practice.
Shimoni A; Nagler A
Cancer Treat Res; 2002; 110():113-36. PubMed ID: 11908195
[TBL] [Abstract][Full Text] [Related]
6. Modeling the interaction between donor-derived regulatory T cells and effector T cells early after allogeneic hematopoietic stem cell transplantation.
Nishiyama N; Ruoff P; Jimenez JC; Miwakeichi F; Nishiyama Y; Yata T
Biosystems; 2023 May; 227-228():104889. PubMed ID: 37019377
[TBL] [Abstract][Full Text] [Related]
7. [Immune tolerance induced by cytokines in allogeneic hematopoietic stem cell transplantation].
Chang YJ; Huang XJ
Beijing Da Xue Xue Bao Yi Xue Ban; 2009 Apr; 41(2):208-11. PubMed ID: 19377632
[TBL] [Abstract][Full Text] [Related]
8. Strategies for Enhancing and Preserving Anti-leukemia Effects Without Aggravating Graft-Versus-Host Disease.
Chang YJ; Zhao XY; Huang XJ
Front Immunol; 2018; 9():3041. PubMed ID: 30619371
[TBL] [Abstract][Full Text] [Related]
9. Hematopoietic stem cell graft manipulation as a mechanism of immunotherapy.
Talmadge JE
Int Immunopharmacol; 2003 Aug; 3(8):1121-43. PubMed ID: 12860168
[TBL] [Abstract][Full Text] [Related]
10. Vitamin D Modifies the Incidence of Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation Depending on the Vitamin D Receptor (VDR) Polymorphisms.
Carrillo-Cruz E; García-Lozano JR; Márquez-Malaver FJ; Sánchez-Guijo FM; Montero Cuadrado I; Ferra I Coll C; Valcárcel D; López-Godino O; Cuesta M; Parody R; López-Corral L; Alcoceba M; Caballero-Velázquez T; Rodríguez-Gil A; Bejarano-García JA; Ramos TL; Pérez-Simón JA
Clin Cancer Res; 2019 Aug; 25(15):4616-4623. PubMed ID: 31043390
[TBL] [Abstract][Full Text] [Related]
11. Sphingolipid metabolism in T cell responses after allogeneic hematopoietic cell transplantation.
Tian L; Ogretmen B; Chung BY; Yu XZ
Front Immunol; 2022; 13():904823. PubMed ID: 36052066
[TBL] [Abstract][Full Text] [Related]
12. The Effects of Interferons on Allogeneic T Cell Response in GVHD: The Multifaced Biology and Epigenetic Regulations.
Zhao C; Zhang Y; Zheng H
Front Immunol; 2021; 12():717540. PubMed ID: 34305954
[TBL] [Abstract][Full Text] [Related]
13. The expanding horizon of immunotherapy in the treatment of malignant disorders: allogeneic hematopoietic stem cell transplantation and beyond.
Tsirigotis P; Shimoni A; Nagler A
Ann Med; 2014 Sep; 46(6):384-96. PubMed ID: 24888385
[TBL] [Abstract][Full Text] [Related]
14. The allure and peril of hematopoietic stem cell transplantation: overcoming immune challenges to improve success.
Newman RG; Ross DB; Barreras H; Herretes S; Podack ER; Komanduri KV; Perez VL; Levy RB
Immunol Res; 2013 Dec; 57(1-3):125-39. PubMed ID: 24272856
[TBL] [Abstract][Full Text] [Related]
15. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
16. Immunomodulatory Effects of Histone Deacetylation Inhibitors in Graft-vs.-Host Disease After Allogeneic Stem Cell Transplantation.
Xu X; Li X; Zhao Y; Huang H
Front Immunol; 2021; 12():641910. PubMed ID: 33732262
[TBL] [Abstract][Full Text] [Related]
17. Expanded donor natural killer cell and IL-2, IL-15 treatment efficacy in allogeneic hematopoietic stem cell transplantation.
Chen G; Wu D; Wang Y; Cen J; Feng Y; Sun A; Tang X; Chang H; Zhu Z
Eur J Haematol; 2008 Sep; 81(3):226-35. PubMed ID: 18573173
[TBL] [Abstract][Full Text] [Related]
18. Baricitinib-induced blockade of interferon gamma receptor and interleukin-6 receptor for the prevention and treatment of graft-versus-host disease.
Choi J; Cooper ML; Staser K; Ashami K; Vij KR; Wang B; Marsala L; Niswonger J; Ritchey J; Alahmari B; Achilefu S; Tsunoda I; Schroeder MA; DiPersio JF
Leukemia; 2018 Nov; 32(11):2483-2494. PubMed ID: 29691471
[TBL] [Abstract][Full Text] [Related]
19. Graft-versus-leukemia and graft-versus-host reactions after donor lymphocyte infusion are initiated by host-type antigen-presenting cells and regulated by regulatory T cells in early and long-term chimeras.
Xia G; Truitt RL; Johnson BD
Biol Blood Marrow Transplant; 2006 Apr; 12(4):397-407. PubMed ID: 16545723
[TBL] [Abstract][Full Text] [Related]
20. Graft-vs-leukemia activity and graft-vs-host disease induced by allogeneic Th1- and Th2-type CD4+ T cells in mice.
Zeis M; Uharek L; Hartung G; Glass B; Steinmann J; Schmitz N
Hematol J; 2001; 2(2):136-44. PubMed ID: 11424006
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
